Back to Stakeholders
Categories

1 domain / 2 areas / 2 specializations

L.E.K. Consulting

Data updated

Global strategy consultancy with US/EU healthcare practices and published analysis on psychedelic treatment pathways, funding dynamics, and commercialization implications.

Consultancy & Advisory Snapshot

Commercial Strategy Consulting

Geography

Global

Coverage

Global

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement

Active

Pipeline Stage Coverage

Clinical DevelopmentMarket Access & HEORCommercialization & Launch

Client Types

Drug DevelopersInvestors / FundsClinical Providers / Care Organizations

Consultancy Notes

L.E.K. Consulting is a global strategy consultancy with more than 200 partners across 27 offices and dedicated life sciences and healthcare practices. It has published repeated psychedelic sector analyses, including a 2021 Executive Insights sizing the psychedelic drug opportunity and a 2024 piece on integrating psychotherapy into psychedelic treatment, which estimated roughly 12,000 additional therapists would be needed in the US. Psychedelics remain one topic within a broad mental and behavioural health practice rather than a dedicated service line.

Verification

Verified

Last Verified

Jul 11, 2026

Primary Service Link

Documented Engagements

Insight publication on psychedelics and psychotherapy

Mar 27, 2024

Authored by partner Adrienne Rivlin; covers investment trends, the three-phase treatment model, the trained-therapist bottleneck and digital capacity options.

Psychedelics and Psychotherapy: A Treatment Paradigm for the Future?

Executive Insights on psychedelic psychiatry market

Jan 1, 2021

Market analysis covering the clinical pipeline of over 40 psychedelic assets, investment surge and commercialisation challenges.

Psychedelic Psychiatry: A Revolution Set to Transform Our Mental Health?

Quick Facts

Type
Other
Website
Visit